Following the US FDA approval of tofacitinib, a JAK3-selective small molecule inhibitor (SMI), for the medical treatment of RA, the critical role of JAK/STAT pathway activation in RA was further confirmed. The gene discussed is JAK3; the disease is rheumatoid arthritis.